Tg Therapeutics (TGTX) Non-Current Debt (2010 - 2026)
Tg Therapeutics (TGTX) posted quarterly Non-Current Debt of $745.1 million for Q1 2026, up 204.47% year-over-year from $244.7 million in Q1 2025, and up 203.34% quarter-over-quarter from $245.6 million in Q4 2025.
Tg Therapeutics (TGTX) Non-Current Debt (2010 - 2026) Analysis & Trends
Tg Therapeutics' Non-Current Debt history runs 15 years deep, the most recent figure standing at $745.1 million for Q1 2026.
- In Q1 2026, Non-Current Debt rose 204.47% year-over-year to $745.1 million; the TTM figure through Mar 2026 stood at $745.1 million (up 204.47% YoY), while the FY2025 annual figure was $245.6 million, changed 0.5% from the prior year.
- Non-Current Debt for Q1 2026 stood at $745.1 million, up from $245.6 million in the prior quarter.
- The five-year high for Non-Current Debt was $745.1 million in Q1 2026, with the low at $67.2 million in Q1 2022.
- The 5-year median for Non-Current Debt is $101.3 million (2024), against an average of $181.8 million.
- The sharpest annual moves came in 2025 and 2026: Non-Current Debt advanced 0.48% in 2025, then soared 204.47% in 2026.
- Tg Therapeutics' Non-Current Debt stood at $71.1 million in 2022, then soared by 40.74% to $100.1 million in 2023, then soared by 144.14% to $244.4 million in 2024, then increased by 0.5% to $245.6 million in 2025, then jumped by 203.34% to $745.1 million in 2026.
- Business Quant data shows TGTX's Non-Current Debt at $745.1 million in Q1 2026, $245.6 million in Q4 2025, and $245.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Tg Therapeutics | 7.46 Bn | 6.78 Bn | 199.14 Mn | 745.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 745.39 Mn |
| Mar 31, 2026 | 745.14 Mn |
| Dec 31, 2025 | 245.65 Mn |
| Sep 30, 2025 | 245.34 Mn |
| Jun 30, 2025 | 245.04 Mn |
| Mar 31, 2025 | 244.73 Mn |
| Dec 31, 2024 | 244.43 Mn |
| Sep 30, 2024 | 244.16 Mn |
| Jun 30, 2024 | 102.54 Mn |
| Mar 31, 2024 | 101.33 Mn |
| Dec 31, 2023 | 100.12 Mn |
| Sep 30, 2023 | 98.91 Mn |
| Jun 30, 2023 | 97.70 Mn |
| Mar 31, 2023 | 96.50 Mn |
| Dec 31, 2022 | 71.14 Mn |
| Sep 30, 2022 | 71.14 Mn |
| Jun 30, 2022 | 68.95 Mn |
| Mar 31, 2022 | 67.25 Mn |
| Dec 31, 2021 | 66.79 Mn |
| Dec 31, 2020 | 7.72 Mn |